Loading

Cytimm Therapeutics

June 05, 2024
Company Presentation
Oncology
Company Presentation Theater 1
Cytimm Therapeutics is a clinical-stage biopharmaceutical company located in San Diego. We are focusing on the development of innovative IL-2 based therapies with First-In-Class potential for cancer, neurodegenerative and autoimmune diseases. Cytimm uses innovative technologies to decouple the two opposite functions of IL-2 and developed two proprietary IL-2 based drugs, CTM103 and CTM201, each targets a spectrum of diseases: CTM103 targets solid tumors including Lung Cancer, Melanoma, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Colon Cancer, Bladder Cancer; CTM201 targets Systemic lupus erythematosus (SLE), Psoriasis, Ulcerative Colitis (UC), Atopic Dermatitis, Amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson's disease. These two “pipeline-in-a-product” assets have the potential to make tremendous impacts, both socially and commercially.
Cytimm Therapeutics
Company Website: http://www.cytimm.com
Lead Product in Development: CTM103
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Company HQ City

San Diego

Company HQ State

CA

Company HQ Country

United States

CEO/Top Company Official

Haining Huang

Development Phase of Primary Product

Phase I
Speakers
Haining Huang, PhD
CEO
Cytimm Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS